The Medical Letter on Drugs and Therapeutics
Drugs for Psoriatic Arthritis (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Psoriatic arthritis is a chronic inflammatory arthropathy that develops in up to 40% of patients with psoriasis. Several guidelines for treatment of psoriatic arthritis have been published.1-4


Nonselective NSAIDs can improve symptoms in patients with mild disease. The selective cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex, and generics) may also be effective; one randomized, double-blind, 12-week trial in patients with a psoriatic arthritis flare found that ACR20 response rates (20% improvement on the American College of Rheumatology scale) with celecoxib 200 or 400 mg daily were superior to those with placebo at week 2, but there was no difference between the groups at week 12.5

Adverse Effects – Worsening of skin disease has been reported when NSAIDs were started in patients ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Psoriatic Arthritis (online only)
Article code: 1470d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian